BridgeMD
A blinded randomized study of two types of reversal agents (neostigmine/glycopyrrolate 50 mikrogram/kg or sugammadex 2 mg/kg) for reversal of neuromuscular blockade in elderly patients (≥ 75 years)
EU CTIS ID: 2023-504230-21-00
What this study is testing
The aim of this study is to determine the time to TOF ≥ 0.9 after either neostigmine/glycopyrrolate 50 mikrogr/kg or sugammadex 2 mg/kg in patients with age ≥ 75 years. The hypothesis of this study is that sugammadex 2 mg/kg provides a faster time to TOF ≥ 0.9 compared to neostigmine/glycopyrrolate 50 mikrogr/kg.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1) Patients ≥ 75 years old
- 2) Informed consent
- 3) Scheduled for robotic assisted laparoscopic surgery under general anesthesia with intubation and use of rocuronium during the entire operation
- 4) American Society of Anesthesiologists (ASA) physical status classification I to IV
- 5) Can read and understand Danish
You likely can't join if
- 1) Known allergy to rocuronium, sugammadex or neostigmine/glycopyrrolate
- 2) Neuromuscular disease that may interfere with neuromuscular data
- 3) Severe renal impairment defined as eGFR < 30 ml/min
- 4) Indication for rapid sequence induction
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.